Comparison of SSRIs and SNRIs in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials

Journal of Clinical Pharmacy and Therapeutics

Volumn 35, Issue 2, 2010, Pages 177-188

  MacHado, M ^a   Einarson, T R ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Major depressive disorder; Meta analysis; Naturalistic studies; Randomized controlled trials; Remission; Selective serotonin reuptake inhibitors; Serotonin and norepinephrine reuptake inhibitors

Indexed keywords

LITHIUM; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; THYROID HORMONE;

ADULT; ARTICLE; CHECKLIST; CHI SQUARE TEST; CLINICAL PROTOCOL; CLINICAL TRIAL; COCHRANE LIBRARY; COMORBIDITY; COMPARATIVE STUDY; CONSENSUS; DATA BASE; ECONOMIC ASPECT; EMBASE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MEDLINE; META ANALYSIS; QUALITY CONTROL; RANDOMIZATION; REMISSION; RISK; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADRENERGIC UPTAKE INHIBITORS; ADULT; DEPRESSIVE DISORDER, MAJOR; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 77749279863     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2009.01050.x     Document Type: Article

References (62)

1. Montes JM, Ferrando L, Jerónimo SR (2004) Remission in major depression with two antidepressant mechanisms. Results from a naturalistic study. Journal of Affective Disorders, 79, 229 234.
2. Mace S, Taylor D (2000) Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression. Expert Opinion in Pharmacotherapy, 1, 917 933.
3. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA (2004) Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. Journal of Clinical Psychopharmacology, 24, 389 399.
4. Thase ME, Entsuah AR, Rudolph RL (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry, 178, 234 241.
5. Tran PV, Bymaster FP, McNamara RK, Potter WZ (2003) Dual monoamine modulation for improved treatment of major depressive disorder. Journal of Clinical Psychopharmacology, 23, 78 86.
6. Baker SG, Kramer BS (2002) The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C? BMC Medical Research Methodology, 13, 2 13.
7. Santaguida PL, Helfand M, Raina P (2005) Challenges in systematic reviews that evaluate drug efficacy or effectiveness. Annals of Internal Medicine, 142, 1066 1072. (Pubitemid 40847709)
8. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002) Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. British Journal of Psychiatry, 180, 396 404.
9. Einarson TR, Arikian SR, Casciano J, Doyle JJ (1999) Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clinical Therapeutics, 21, 296 308.
10. Prien RF, Carpenter LL, Kupfer DJ (1991) The definition and operational criteria for treatment outcome of major depressive disorder. A review of the current research literature. Archives of General Psychiatry, 48, 796 800.
11. Frank E, Prien RF, Jarret RB et al. (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Archives of General Psychiatry, 48, 851 855.
12. Fava GA, Grandhi S, Zielezny M et al. (1996) Four-year outcome for cognitive behavioral treatment of residual symptoms in major depression. American Journal of Psychiatry, 153, 945 947.
13. Miller IW, Keitner GI, Schatzberg AF et al. (1998) The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. Journal of Clinical Psychiatry, 59, 608 619.
14. Guy W (1976) ECDEU Assessment manual for psychopharmacology. Publication ADM 76-338. Rockville, MD : US Department of Health, Education and Welfare, 217 222.
15. Zimmerman M, Posternak MA, Chelminski I (2004) Implications of using different cut-offs on symptom severity scales to define remission from depression. International Clinical Psychopharmacology, 19, 215 220.
16. Thase ME, Simons AD, McGeary J et al. (1992) Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. American Journal of Psychiatry, 149, 1046 1052.
17. Fava GA, Fabbri S, Sonino N (2002) Residual symptoms in depression: an emerging therapeutic target. Biological Psychiatry, 26, 1019 1027. (Pubitemid 35256092)
18. Reesal RT, Lam RW (2001) Clinical guidelines for the treatment of depressive disorders. II. Principles of management. Canadian Journal of Psychiatry, 46, 21S 28S.
19. Rush AJ, Trivedi MH (1995) Treating depression to remission. Psychiatric Annals, 25, 704 705.
20. Thase ME (2001) The clinical, psychosocial, and pharmacoeconomic ramifications of remission. American Journal of Managed Care, 7, 377S 385S.
21. Entsuah AR, Huang H, Thase ME (2001) Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. Journal of Clinical Psychiatry, 62, 869 877.
22. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. Washington : American Psychiatric Association.
23. Hamilton M (1960) A rating scale for depression. Journal of Neurology and Neurosurgical Psychiatry, 23, 56 62.
24. Montgomery SA, Åsberg M (1979) A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382 389.
25. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088 1101.
26. Duval S, Tweedie R (2000) A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics, 56, 455 463.
27. Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. Journal of Epidemiology and Community Health, 52, 377 384.
28. Bagby RM, Kennedy SH, Schuller DR et al. (1997) Differential pharmacological treatment response in high angry hostile and low angry hostile depressed patients: a retrospective analysis. Journal of Affective Disorders, 45, 161 166.
29. Clerc GE, Ruimy P, Verdeau-Palles J (1994) A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. International Clinical Psychopharmacology, 9, 139 143.
30. De Nayer A, Geerts S, Ruelens L et al. (2002) Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. International Journal of Neuropsychopharmacology, 5, 115 120.
31. Poirier MF, Boyer P (1999) Venlafaxine and paroxetine in treatment-resistant depression. Double- blind, randomised comparison. British Journal of Psychiatry, 175, 12 16.
32. Silverstone PH, Ravindran A (1999) Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. Journal of Clinical Psychiatry, 60, 22 28.
33. Tzanakaki M, Guazzelli M, Nimatoudis I, Zissis NP (2000) Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. International Clinical Psychopharmacology, 15, 29 34.
34. Arias F, Padin JJ, Gilaberte I et al. (1998) Comparative naturalistic study of the efficacy and tolerability of new antidepressants. Actas Luso Españolas de Neurologia Psiquiatria y Ciencias Afines, 26, 351 357.
35. Diaz-Martinez A, Benassinni O, Ontiveros A et al. (1998) A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clinical Therapeutics, 20, 467 476.
36. Dierick M, Ravizza L, Realini R et al. (1996) A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Biological Psychiatry, 20, 57 71.
37. Bielski R, Ventura D, Chang C, Korotzer A (2003) Double-blind comparison of escitalopram and venlafaxine XR in the treatment of major depressive disorder. European Neuropsychopharmacology, 13, S263.
38. Schatzberg AF, Cantillon M (2000) Antidepressant early response and remission of venlafaxine and fluoxetine in geriatric outpatients. European Neuropsychopharmacology, 10, S225 S226.
39. McPartlin GM, Reynolds A, Anderson C, Casoy J (1998) A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Primary Care Psychiatry, 4, 127 132.
40. Rudolph R, Entsuah R, Aguiar L, Derivan A (1998) Early onset of antidepressant activity of venlafaxine compared with placebo and fluoxetine in outpatients in a double-blind study. European Neuropsychopharmacology, 8, S142.
41. Tylee A, Beaumont G, Bowden M et al. (1997) A double-blind randomised 12 week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe depression in general practice. Primary Care Psychiatry, 3, 51 58.
42. Stahl SM, Entsuah R, Rudolph RL (2002) Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biological Psychiatry, 52, 1166 1174.
43. Nemeroff CB, Schatzenberg AF, Goldstein DJ et al. (2002) Duloxetine for the treatment of major depressive disorder. Psychopharmacology Bulletin, 36, 106 132.
44. Alves C, Cachola I, Brandao J (1999) Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. Primary Care Psychiatry, 5, 57 63.
45. Bielski RJ, Ventura D, Chang CC (2004) A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. Journal of Clinical Psychiatry, 65, 1190 1196.
46. Costa e Silva J (1998) Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. Journal of Clinical Psychiatry, 59, 352 357.
47. Detke MJ, Wiltse CG, Mallinckrodt CH et al. (2004) Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo and Paroxetine controlled trial. European Neuropsychopharmacology, 14, 457 470.
48. Ballus C, Quiros G, De Flores T et al. (2000) The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. International Clinical Psychopharmacology, 15, 43 48.
49. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA (2002) Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. Journal of Clinical Psychiatry, 63, 225 231.
50. Mehtonen OP, Søgaard J, Roponen P, Behnke K (2000) Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Journal of Clinical Psychiatry, 61, 95 100.
51. Montgomery SA, Huusom AK, Bothmer J (2004) A randomized study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology, 50, 57 64.
52. Nierenberg AA, Greist JH, Mallinckrodt CH et al. (2007) Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Current Medical Research and Opinion, 23, 401 416.
53. Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ (2006) Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. European Psychiatry, 21, 367 378.
54. Rudolph RL, Feiger AD (1999) A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. Journal of Affective Disorders, 56, 171 181.
55. Schatzberg A, Roose S (2006) A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. American Journal of Geriatric Psychiatry, 14, 361 370.
56. Shelton RC, Haman KL, Rapaport MH et al. (2006) A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. Journal of Clinical Psychiatry, 67, 1674 1681.
57. Sir A, D'Souza RF, Uguz S et al. (2005) Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. Journal of Clinical Psychiatry, 66, 1312 1320.
58. Sheiner LB, Rubin DB (1995) Intention-to-treat analysis and the goals of clinical trials. Clinical Pharmacology and Therapeutics, 57, 6 15.
59. Einarson TR (2004) Evidence based review of escitalopram in treating major depressive disorder in primary care. International Clinical Psychopharmacology, 19, 305 310.
60. Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME (2008) Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biological Psychiatry, 63, 424 434.
61. Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ (2007) Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. Journal of Clinical Psychopharmacology, 27, 672 676.
62. Spencer CM, Wilde MI (1998) Milnacipran. A review of its use in depression. Drugs, 56, 405 427.